Actively Recruiting

Phase 2
Age: 40Years +
All Genders
ID07036523

A Double-blind, Randomised, Placebo-controlled Trial to Evaluate BI 765423 Infusion With or Without Standard Treatment in Adults With Idiopathic Pulmonary Fibrosis

Led by Boehringer Ingelheim · Updated on 2026-05-27

71

Participants Needed

47

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating a medicine called BI 765423 in adults aged 40 years and older who have idiopathic pulmonary fibrosis (IPF). The study aims to find out if BI 765423 can improve lung function compared to a placebo over a 3-month period. Participants must have confirmed lung fibrosis of 20% or more and a forced vital capacity (FVC) of at least 45% predicted, with diagnosis verified by high-resolution CT scans. Participants are randomly assigned to one of two groups: one receives BI 765423 and the other receives a placebo that looks like the medicine but contains no active drug. The study medicine is given as an intravenous infusion every four weeks. Participants may continue their regular IPF treatment during the study. The total study duration is 8 to 10 months, including screening, treatment, and follow-up periods. During the study, participants visit the study site several times for lung function tests, including measuring FVC, and blood samples are taken to assess markers related to lung health. The main outcome measured is the change in lung capacity after 12 weeks. Other assessments include walking distance during a 6-minute walk test and oxygen levels at rest. Health and any side effects are regularly monitored throughout the study.

CONDITIONS

Brief Title

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 40 years of age or older at the time of informed consent.
  • Signed informed consent according to ICH-GCP and local laws.
  • Male or female; women must be of non-childbearing potential or surgically sterilised.
  • Documented diagnosis of idiopathic pulmonary fibrosis (IPF) confirmed by guidelines and biopsy if available.
  • High-resolution CT scan within 12 months showing UIP or probable UIP pattern, confirmed by central review.
  • Lung fibrosis extent of 20% or more confirmed by CT scan.
  • Forced vital capacity (FVC) of at least 45% predicted at Visit 1.
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) of at least 20% predicted at Visit 1.
Not Eligible

You will not qualify if you...

  • Acute exacerbation of IPF within 12 weeks before Visit 1 or during screening.
  • Significant airway obstruction with FEV1/FVC ratio less than 0.7 at Visit 1.
  • Recent lower respiratory tract infection needing treatment within 4 weeks before Visit 1 or during screening.
  • Significant pulmonary hypertension or right heart failure.
  • Treatment with nintedanib or pirfenidone for less than 12 weeks before Visit 1, or planned changes to these treatments during first 12 weeks of study drug.
  • Severe cardiovascular conditions including uncontrolled hypertension, recent heart attack, stroke, or unstable angina.
  • Life expectancy under 2.5 years due to other diseases besides IPF.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 12 weeks

Participants receive BI 765423 or placebo infusions to evaluate effects on lung function.

Baseline visit and follow-up visits at 12 weeks

Trial Site Locations

Total: 47 locations

1

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Banner - University Medical Center Tucson

Tucson, Arizona, United States, 85724

Not Yet Recruiting

3

University of Florida

Gainesville, Florida, United States, 32610

Not Yet Recruiting

4

Renstar Medical Research

Ocala, Florida, United States, 34470

Actively Recruiting

5

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States, 52242

Not Yet Recruiting

6

University of Kansas Medical Center

Kansas City, Kansas, United States, 66103-2937

Not Yet Recruiting

7

University of Minnesota

Minneapolis, Minnesota, United States, 55455

Not Yet Recruiting

8

The Lung Research Center, LLC

Chesterfield, Missouri, United States, 63017

Actively Recruiting

9

University of Missouri Health System

Columbia, Missouri, United States, 65212

Not Yet Recruiting

10

Columbia University Medical Center-New York Presbyterian Hospital

New York, New York, United States, 10032

Actively Recruiting

11

Weill Cornell Medical College

New York, New York, United States, 10065

Not Yet Recruiting

12

Duke University Medical Center

Durham, North Carolina, United States, 27710

Not Yet Recruiting

13

University of Cincinnati Medical Center

Cincinnati, Ohio, United States, 45267

Not Yet Recruiting

14

Temple University Hospital

Philadelphia, Pennsylvania, United States, 19140

Actively Recruiting

15

Clinical Trials Center of Middle Tennessee, LLC

Franklin, Tennessee, United States, 37067

Actively Recruiting

16

University of Virginia Health System

Charlottesville, Virginia, United States, 22908

Not Yet Recruiting

17

The Prince Charles Hospital

Chermside, Queensland, Australia, 4032

Actively Recruiting

18

Monash Health

Clayton, Victoria, Australia, 3168

Actively Recruiting

19

Institute for Respiratory Health

Nedlands, Western Australia, Australia, 6009

Actively Recruiting

20

Cliniques Universitaires Saint-Luc

Brussels, Belgium, 1200

Not Yet Recruiting

21

Yvoir - UNIV UCL de Mont-Godinne

Yvoir, Belgium, 5530

Not Yet Recruiting

22

Synergy Respiratory Care

Sherwood Park, Alberta, Canada, T8H 0N2

Actively Recruiting

23

Kelowna Respirology & Allergy Research

Kelowna, British Columbia, Canada, V1Y 3H5

Actively Recruiting

24

QEII Health Sciences Centre

Halifax, Nova Scotia, Canada, B3H 3A7

Not Yet Recruiting

25

Centre Hospitalier de l'Universite de Montreal (CHUM)

Montreal, Quebec, Canada, H2X 0A9

Actively Recruiting

26

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

Essen, Germany, 45239

Actively Recruiting

27

Medizinische Hochschule Hannover

Hanover, Germany, 30625

Actively Recruiting

28

ASST Papa Giovanni XXIII

Bergamo, Italy, 24127

Not Yet Recruiting

29

A. O. Universitaria Careggi

Florence, Italy, 50137

Not Yet Recruiting

30

A.O. dei Colli

Naples, Italy, 80131

Not Yet Recruiting

31

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy, 00168

Actively Recruiting

32

Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino

Torino, Italy, 10126

Actively Recruiting

33

Tosei General Hospital

Aichi, Seto, Japan, 489-8642

Not Yet Recruiting

34

University of Fukui Hospital

Fukui, Yoshida-gun, Japan, 910-1193

Actively Recruiting

35

National Hospital Organization Kyushu Medical Center

Fukuoka, Fukuoka, Japan, 810-8563

Actively Recruiting

36

Kanagawa Cardiovascular and Respiratory Center

Kanagawa, Yokohama, Japan, 236-0051

Actively Recruiting

37

National Hospital Organization Kinki-Chuo Chest Medical Center

Osaka, Sakai, Japan, 591-8555

Actively Recruiting

38

Hamamatsu University Hospital

Shizuoka, Hamamatsu, Japan, 431-3192

Actively Recruiting

39

Soon Chun Hyang University Hospital Bucheon

Bucheon-si, Gyeonggi-do, South Korea, 14584

Actively Recruiting

40

Inje University Haeundae Paik Hospital

Busan, South Korea, 48108

Actively Recruiting

41

Soonchunhyang University Hospital Seoul

Seoul, South Korea, 04401

Actively Recruiting

42

Hospital Vall Hebron

Barcelona, Spain, 08035

Actively Recruiting

43

Hospital Universitari de Bellvitge

L Hospitalet Del Llobregat, Spain, 08907

Actively Recruiting

44

Hospital Universitario De La Princesa

Madrid, Spain, 08035

Actively Recruiting

45

Hospital Virgen del Rocío

Seville, Spain, 41013

Not Yet Recruiting

46

Cantonal Hospital of Aarau

Aarau, Switzerland, 5001

Actively Recruiting

47

Universitätsspital Basel

Basel, Switzerland, 4031

Not Yet Recruiting

Loading map...

Research Team

B

Boehringer Ingelheim

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Phase I, Single-center, Randomized, Double-blind, Single-d...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

An Open-label Extension Trial of the Long-term Safety and Ef...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

373 locations

A Randomized, Double-blind, Placebo-controlled, Single and M...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here